FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894424410> ?p ?o ?g. }

• W2894424410 endingPage "e1502905" @default.
• W2894424410 startingPage "e1502905" @default.
• W2894424410 abstract "Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in other cancers. In this pilot study, we tested TIL based ACT in patients with metastatic OC.Methods:Six patients with progressive platinum-resistant metastatic OC were treated with an infusion of TIL preceded by standard lymphodepleting chemotherapy and followed by decrescendo intravenous interleukin-2 (IL-2). Primarily, the feasibility and tolerability of the treatment was assessed. Secondarily, disease control rate was described and immune responses against tumor cells were monitored.Results:Treatment was well tolerated with manageable toxicities. Four patients had stable disease for three months and two patients for five months with five patients having a decrease in target lesions. Progression was primarily due to new lesions while target lesions in general remained stable or in regression. Antitumor reactivity was observed in TIL infusion products from five patients but no antitumor reactivity was detectable in peripheral blood lymphocytes collected after treatment. High numbers of infused TIL expressed exhaustion markers including LAG3 and PD-1, and immunostaining of tumor tissue demonstrated substantial MHCII and PD-L1 expression.Conclusions:ACT with TIL in combination with decrescendo IL-2 is feasible in patients with metastatic OC. Early indications of clinical activity were found. However, TIL ACT efficacy was incomplete with possible involvement of the inhibitory immune checkpoint pathways LAG3/MHCII and PD1/PD-L1." @default.
• W2894424410 created "2018-10-05" @default.
• W2894424410 creator A5001378278 @default.
• W2894424410 creator A5001457252 @default.
• W2894424410 creator A5008379847 @default.
• W2894424410 creator A5025825017 @default.
• W2894424410 creator A5032476205 @default.
• W2894424410 creator A5033740747 @default.
• W2894424410 creator A5035665900 @default.
• W2894424410 creator A5036265924 @default.
• W2894424410 creator A5037890060 @default.
• W2894424410 creator A5048015974 @default.
• W2894424410 creator A5051043977 @default.
• W2894424410 creator A5057829284 @default.
• W2894424410 creator A5058837420 @default.
• W2894424410 creator A5066165449 @default.
• W2894424410 creator A5071348017 @default.
• W2894424410 creator A5073820582 @default.
• W2894424410 creator A5086241666 @default.
• W2894424410 date "2018-09-26" @default.
• W2894424410 modified "2023-10-10" @default.
• W2894424410 title "Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study" @default.
• W2894424410 cites W1986215428 @default.
• W2894424410 cites W1990602451 @default.
• W2894424410 cites W1994993231 @default.
• W2894424410 cites W1995621823 @default.
• W2894424410 cites W2018235031 @default.
• W2894424410 cites W2019607817 @default.
• W2894424410 cites W2021472146 @default.
• W2894424410 cites W2026897505 @default.
• W2894424410 cites W2029264801 @default.
• W2894424410 cites W2034745242 @default.
• W2894424410 cites W2039897919 @default.
• W2894424410 cites W2041143310 @default.
• W2894424410 cites W2068854353 @default.
• W2894424410 cites W2097105130 @default.
• W2894424410 cites W2103164876 @default.
• W2894424410 cites W2106428332 @default.
• W2894424410 cites W2108113014 @default.
• W2894424410 cites W2113847305 @default.
• W2894424410 cites W2125974203 @default.
• W2894424410 cites W2132923173 @default.
• W2894424410 cites W2137074525 @default.
• W2894424410 cites W2142047025 @default.
• W2894424410 cites W2143467222 @default.
• W2894424410 cites W2147622445 @default.
• W2894424410 cites W2148523692 @default.
• W2894424410 cites W2149209349 @default.
• W2894424410 cites W2150640296 @default.
• W2894424410 cites W2155026493 @default.
• W2894424410 cites W2155189639 @default.
• W2894424410 cites W2155263737 @default.
• W2894424410 cites W2162184613 @default.
• W2894424410 cites W2309691699 @default.
• W2894424410 cites W2337542996 @default.
• W2894424410 cites W2597772749 @default.
• W2894424410 cites W2917837889 @default.
• W2894424410 cites W4238682651 @default.
• W2894424410 doi "https://doi.org/10.1080/2162402x.2018.1502905" @default.
• W2894424410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6279323" @default.
• W2894424410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30524900" @default.
• W2894424410 hasPublicationYear "2018" @default.
• W2894424410 type Work @default.
• W2894424410 sameAs 2894424410 @default.
• W2894424410 citedByCount "74" @default.
• W2894424410 countsByYear W28944244102018 @default.
• W2894424410 countsByYear W28944244102019 @default.
• W2894424410 countsByYear W28944244102020 @default.
• W2894424410 countsByYear W28944244102021 @default.
• W2894424410 countsByYear W28944244102022 @default.
• W2894424410 countsByYear W28944244102023 @default.
• W2894424410 crossrefType "journal-article" @default.
• W2894424410 hasAuthorship W2894424410A5001378278 @default.
• W2894424410 hasAuthorship W2894424410A5001457252 @default.
• W2894424410 hasAuthorship W2894424410A5008379847 @default.
• W2894424410 hasAuthorship W2894424410A5025825017 @default.
• W2894424410 hasAuthorship W2894424410A5032476205 @default.
• W2894424410 hasAuthorship W2894424410A5033740747 @default.
• W2894424410 hasAuthorship W2894424410A5035665900 @default.
• W2894424410 hasAuthorship W2894424410A5036265924 @default.
• W2894424410 hasAuthorship W2894424410A5037890060 @default.
• W2894424410 hasAuthorship W2894424410A5048015974 @default.
• W2894424410 hasAuthorship W2894424410A5051043977 @default.
• W2894424410 hasAuthorship W2894424410A5057829284 @default.
• W2894424410 hasAuthorship W2894424410A5058837420 @default.
• W2894424410 hasAuthorship W2894424410A5066165449 @default.
• W2894424410 hasAuthorship W2894424410A5071348017 @default.
• W2894424410 hasAuthorship W2894424410A5073820582 @default.
• W2894424410 hasAuthorship W2894424410A5086241666 @default.
• W2894424410 hasBestOaLocation W28944244101 @default.
• W2894424410 hasConcept C121608353 @default.
• W2894424410 hasConcept C126322002 @default.
• W2894424410 hasConcept C143998085 @default.
• W2894424410 hasConcept C197934379 @default.
• W2894424410 hasConcept C203014093 @default.
• W2894424410 hasConcept C2777658100 @default.
• W2894424410 hasConcept C2777701055 @default.
• W2894424410 hasConcept C2778326572 @default.

• next